IN THE CLAIMS

Claims 1-7 (canceled).

8. (Currently amended) A method for treating <u>*Hemophilus influenza*</u> [bacterial] infections of an upper respiratory tract, wherein the method comprises delivering to the mouth, throat or nasal passages a composition comprising:

(i) an effective amount of at least one lytic enzyme genetically coded for by a bacteriophage specific for [a bacteria that causes said bacterial infections of said upper respiratory tract] <u>said *Hemophilus influenza*</u>, said at least one lytic enzyme having the ability to <u>specifically</u> digest a cell wall of <u>said *Hemophilus influenza*</u> [a specific said bacteria wherein said bacteria to be treated is selected from the group consisting of *Streptococcus pneumoniae* and *Hemophilus influenza*]; and

ii) a carrier for delivering said enzyme to a mouth, throat, or nasal passage..

9. (Canceled).

10. (Canceled)

11.(Canceled)

12. (Original) The method according to claim 8, wherein said carrier is a candy, chewing gum, lozenge, troche, tablet, a powder, an aerosol, a liquid and a liquid spray.

13. (Original) The method according to claim 8, wherein said composition further comprises a buffer that maintains pH of the composition at a range between about 4.0 and about 9.0.

14. (Original) The method according to claim 13, wherein the buffer maintains the pH of the composition at the range between about 5.5 and about 7.5.

15. (Original) The method according to claim 13, wherein said buffer comprises a reducing reagent.

16. (Original) The method according to claim 15, wherein said reducing reagent is dithiothreitol.

17. (Original) The method according to claim 13, wherein said buffer comprises a metal chelating reagent.

18. (Original) The method according to claim 17, wherein said metal chelating reagent is ethylenediaminetetracetic disodium salt.

19. (Original) The method according to claim 13, wherein said buffer is a citrate-phosphate buffer.

20. (Original) The method according to claim 8, further comprising a bactericidal or

bacteriostatic agent as a preservative.

21. (Original) The method according to claim 8, wherein said at least one lytic enzyme is lyophilized.

22. (Original) The method according to claim 8, wherein said carrier further comprises a sweetener.

23. (Original) The method according claim 8, further comprising administering a concentration of about 100 to about 100,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.

24. (Previously amended) The method according to claim [24] 23, further comprising administering the concentration of about 100 to about 10,000 active enzyme units per milliliter of fluid in the wet environment of the nasal or oral passages.

25. (Canceled)

26. (Canceled)

27. (Canceled)

28. (Canceled)